This is because the GPC3 peptide vaccine is not yet a standard treatment for ovarian cancer, and the study sample was obtained from limited and valuable samples in the phase II study of the GPC3 peptide vaccine. This evidence concerns the gene GPC3 and ovarian carcinoma.